Xu Qing-Hua, Huang Song-Ping, Li Wen-Lan, Ye Xiao-Yi, Lin Xian-Hui, Wu Yan-Ling, Chen Xiao-Fang, Zhuang Xi-Bin
Clin Lab. 2020 Oct 1;66(10). doi: 10.7754/Clin.Lab.2020.200244.
CC chemokine ligand-18 (CCL-18) and CX3 chemokine ligand 1 (CX3CL1) are key factors of vascular and tissue injury in chronic respiratory diseases. Here, we investigated the value of CCL-18 and CX3CL1 in diagnosis and prognosis of patients with chronic obstructive pulmonary disease and chronic cor pulmonale (COPD&CCP).
First, we investigated the expression profile of CCL-18 and CX3CL1 in serum of COPD&CCP patients. Then the relationship of the level of CCL-18 and CX3CL1 with clinicopathological characteristics was analyzed. Subsequently, we evaluated the diagnostic accuracy of CCL-18 and CX3CL1 to discriminate COPD&CCP. The prognostic value and therapy outcome were also evaluated.
Compared to healthy subjects, the level of CCL-18 (8.01 ± 2.01 ng/mL) and CX3CL1 (2,096.11 ± 306.09 ng/mL) was significantly increased in COPD&CCP patients (p < 0.05). The upregulation of CCL-18 and CX3CL1 was significantly correlated with clinicopathological characteristics including CRP, IL-6, FIB, NT-proBNP, FEV1, FEV1/FVC, PASP, LVEF, and T wave anomaly. The combination of CCL-18 and CX3CL1 showed high precision for discriminating COPD&CCP with high AUC values (0.828), sensitivity (66.1%), and specificity (92.5%). Furthermore, CCL-18 and CX3CL1 acted as independent factors which lead to poor clinical benefits and indicated poor prognosis of COPD&CCP patients.
Taken together, our results indicated that CCL-18 and CX3CL1 could act as suitable biomarkers in prognosis and prognostic evaluation of COPD&CCP.
CC趋化因子配体18（CCL-18）和CX3趋化因子配体1（CX3CL1）是慢性呼吸道疾病中血管和组织损伤的关键因素。在此，我们研究了CCL-18和CX3CL1在慢性阻塞性肺疾病合并慢性肺源性心脏病（COPD&CCP）患者诊断和预后中的价值。
首先，我们研究了COPD&CCP患者血清中CCL-18和CX3CL1的表达谱。然后分析了CCL-18和CX3CL1水平与临床病理特征的关系。随后，我们评估了CCL-18和CX3CL1鉴别COPD&CCP的诊断准确性。还评估了其预后价值和治疗效果。
与健康受试者相比，COPD&CCP患者中CCL-18（8.01±2.01 ng/mL）和CX3CL1（2,096.11±306.09 ng/mL）水平显著升高（p<0.05）。CCL-18和CX3CL1的上调与包括CRP、IL-6、FIB、NT-proBNP、FEV1、FEV1/FVC、PASP、LVEF和T波异常在内的临床病理特征显著相关。CCL-18和CX3CL1的联合检测在鉴别COPD&CCP方面显示出高精度，AUC值高（0.828），敏感性（66.1%）和特异性（92.5%）。此外，CCL-18和CX3CL1是导致临床获益不佳的独立因素，提示COPD&CCP患者预后不良。
综上所述，我们的结果表明CCL-18和CX3CL1可作为COPD&CCP预后和预后评估的合适生物标志物。
